ストックスクリーナーアプリを入手
1.46
3.95%
-0.06
アフターアワーズ：
1.48
0.02
+1.37%
前日終値:
$1.52
開ける：
$1.5
24時間の取引高:
376.27K
Relative Volume:
0.18
時価総額：
$22.12M
収益：
$2.79M
当期純損益:
$9.17M
株価収益率:
1.0665
EPS:
1.369
ネットキャッシュフロー:
$-20.77M
1週間 パフォーマンス:
-2.01%
1か月 パフォーマンス:
+12.31%
6か月 パフォーマンス:
-45.93%
1年 パフォーマンス:
+5.04%
1日の値動き範囲:
$1.45
$1.54
1週間の範囲:
$1.45
$1.7199
52週間の値動き範囲:
$0.995
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.46 | 23.03M | 2.79M | 9.17M | -20.77M | 1.369 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | 開始されました | H.C. Wainwright | Buy |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-05-18 | 開始されました | Guggenheim | Buy |
| 2018-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-09 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-27 | 開始されました | Laidlaw | Buy |
| 2015-07-01 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Traws Pharma Inc (TRAW) 最新ニュース
TRAW | Traws Pharma, Inc. Common Executive Compensation - Quiver Quantitative
Traws Pharma (NASDAQ: TRAW) 2026 proxy seeks share plan and warrant approvals - Stock Titan
Traws Pharma announces new antiviral program - BioWorld News
Newtown-based Traws Pharma advances experimental antiviral therapy - Pennsylvania Business Report -
TRAW Advances Novel Anti-Viral Agent for Hantavirus and Ebola - GuruFocus
Traws Pharma Advances Novel Broad-Spectrum Antiviral Agent Targeting Hantavirus, Ebola, and Lassa with Innovative Dual-Strike Mechanism - Quiver Quantitative
Traws Pharma (NASDAQ: TRAW) advances broad antiviral for Hantavirus, Ebola - Stock Titan
New dual-strike pill aims to tackle deadly Ebola and hantavirus outbreaks - Stock Titan
Traws Pharma, Inc. Files Form 8-K with SEC – Company Details, Address, and Legal Opinion Included - Minichart
TRAW - Finviz
Traws Pharma launches $3.13M ATM sales under $50M shelf with Citizens JMP - TradingView
Traws Pharma (NASDAQ: TRAW) outlines $3,128,399 baby shelf ATM capacity - Stock Titan
Traws Pharma (TRAW) Stock Forecast & Analyst Ratings - Moomoo
Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Better-than-Expected Losses Highlight Cost Discipline Amid Pre-Revenue PhaseElite Trading Signals - Newser
Traws Pharma Q1 2026 Earnings: Narrower Than Expected Loss Despite No RevenueStock Idea Network - Newser
Traws Extends Runway With Financing as Flu Trial Nears - MyChesCo
Traws Pharma Inc files for offering of up to $3.1 million in common stock - marketscreener.com
Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock - TradingView
TRAW (NASDAQ: TRAW) expands ATM by $3.13M under Citizens JMP agreement - Stock Titan
TRAW Stock Chart | TRAWS PHARMA INC (NASDAQ:TRAW) - ChartMill
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
TRAW Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Buy on Traws Pharma stock, $8 target By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on Traws Pharma stock, $8 target - Investing.com
Traws Pharma (TRAW) asks shareholders to approve 2M-share plan increase, auditor ratification - Stock Titan
Traws Pharma Company Profile & Introduction - Moomoo
[EFFECT] Traws Pharma, Inc. SEC Filing - Stock Titan
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results - Sahm
Traws Pharma 1Q Loss/Shr 53c >TRAW - Moomoo
Traws Pharma (TRAW) registers 35.9M resale shares including warrants - Stock Titan
Traws Pharma, Inc. Q1 2026 Financial Results & Quarterly SEC Filing Highlights - Minichart
Perceptive (NASDAQ: TRAW) reports 6.1% stake via 979,815 warrants - Stock Titan
Traws Pharma 1Q Rev $0.00 >TRAW - Moomoo
Traws Pharma Releases Q1 2026 Financial Results - AlphaStreet
Traws Pharma Secures $60M Financing, Advances Tivoxavir Marboxil for Influenza and Hantavirus Programs in Q1 2026 Financial Results - Minichart
Traws Pharma (NASDAQ: TRAW) group holds 6.4% (511,714 shares) - Stock Titan
Once-a-month flu shield and hantavirus drug: Traws secures $10M, up to $60M - Stock Titan
Is Traws Pharma (TRAW) a Possible Value Trap After Q1 2026? EPS - GuruFocus
Traws Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Traws Pharma Highlights Q1 Results and Antiviral Pipeline Progress - TipRanks
Traws Pharma, Inc. 1Q 2026: Revenue $0 EPS $(0.53) — 10-Q Summary - TradingView
Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Traws Pharma, Inc. Quarterly Earnings Report - Stock Titan
Traws Pharma reports Q1 net loss on higher R&D expenses - TradingView
Traws Pharma (NASDAQ: TRAW) details $60M PIPE and Q1 2026 results - Stock Titan
BRIEF-Traws Pharma Inc Q1 Revenue USD 0 - TradingView
Traws Pharma, Inc.Common Stock (NQ: TRAW - FinancialContent
Traws Pharma Inc (TRAW) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
1.35%
大文字化:
|
ボリューム (24 時間):